-
Morgan Stanley Comments on Gen-Probe's New Product CLEAR (GPRO)
Wednesday, May 4, 2011 - 8:43am | 148Morgan Stanley provided color on Gen-Probe's (NASDAQ: GPRO) new product pipeline in a research report published today. Morgan Stanley commented specifically on the "commercial and financial implications of the US clinical trial data for Aptima HPV called CLEAR that will be presented this weekend...
-
Morgan Keegan Comments On Masimo Corporation Following Recent Earnings Release
Wednesday, May 4, 2011 - 8:13am | 186Masimo Corporation (NASDAQ: MASI) reported 1Q results with sales that were slightly above the consensus and in-line EPS. Despite the tough hospital environment, Masimo continues to execute with record product sales and driver placements as the company's SET and Rainbow parameters gain market share...
-
NxStage Advances Global Growth Strategy with System One Regulatory Approval and Distribution Agreement in Australia and New Zealand (NXTM)
Wednesday, May 4, 2011 - 8:09am | 115NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that it has received regulatory approval from Australia's Therapeutic Goods Administration for the NxStage System One™ and signed a five-year agreement, the first year of which is exclusive...
-
Piper Jaffray Comments On Masimo 1Q11 Results
Wednesday, May 4, 2011 - 7:31am | 112According to Piper Jaffray, Masimo (NASDAQ: MASI) reported 1Q11 revenue above its and Street consensus expectations, with in-line EPS. Piper Jaffray said that rainbow was below estimate due to the timing of last year's large military order, but much stronger than expected SET revenue drove 1Q11...
-
UPDATE: J.P. Morgan Raising Price Target On Thoratec Corp. (THOR)
Wednesday, May 4, 2011 - 7:30am | 268J.P. Morgan Chase & Co. is raising its price target on shares of Thoratec Corp. (NASDAQ: THOR) to $32 up from $28, and it has a Neutral rating on shares. In a note to investors, J.P. Morgan writes, "Thoratec reported mixed 1Q results Tuesday after the close, with total revenues of $99.5M (flat...
-
Integra LifeSciences Announces Three-Year Contract With Novation to Provide Luxtec Surgical Headlights (IART)
Wednesday, May 4, 2011 - 7:09am | 115Integra LifeSciences Holdings Corporation (Nasdaq: IART) announced today that it has signed a three-year contract with Novation, the leading healthcare supply contracting company, to provide Luxtec® surgical headlights, light sources and accessories to the members of VHA Inc., University...
-
JP Morgan Raises PT On Thoratec To $32
Wednesday, May 4, 2011 - 6:10am | 26JP Morgan has raised the price target on Thoratec (NASDAQ: THOR) from $28 to $32 and maintains its Neutral rating.
-
Thoratec Reports 1Q ADJ EPS of $0.34 vs. $0.33 Estimate; Revenues $99.5M vs. $100.16M Estimate
Tuesday, May 3, 2011 - 4:36pm | 23Thoratec (NASDAQ: THOR) Reports 1Q ADJ EPS of $0.34 vs. $0.33 Estimate; Revenues $99.5M vs. $100.16M Estimate
-
American Medical Systems Reports EPS of $0.33 vs. $0.30 Estimate; Revenues $140.8M vs. $137.1M Estimate
Tuesday, May 3, 2011 - 4:17pm | 23American Medical Systems (NASDAQ: AMMD) Reports EPS of $0.33 vs. $0.30 Estimate; Revenues $140.8M vs. $137.1M Estimate
-
DexCom Announces Board Additions; Names Kevin Sayer President (DXCM)
Tuesday, May 3, 2011 - 4:02pm | 106DexCom, Inc. (NASDAQ: DXCM) today announced the appointment of two independent directors, Barbara E. Kahn and Martin L. “Chip” Doordan. Barbara E. Kahn currently serves as the Patty and Jay H. Baker Professor of Marketing and the Director of the Jay H. Baker Retailing Center at The Wharton School...
-
Masimo Corp Reports EPS of $0.30 vs. $0.30 Estimate; Revenues $113M vs. $110.7M Estimate (MASI)
Tuesday, May 3, 2011 - 4:01pm | 22Masimo Corp (NASDAQ: MASI) Reports EPS of $0.30 vs. $0.30 Estimate; Revenues $113M vs. $110.7M Estimate
-
PatternDNA - CANSLIM Analysis May 3rd.
Tuesday, May 3, 2011 - 10:02am | 1245Last week saw a shuffle in our CANSLIM Top-8 with the return of Netflix (NFLX) and F5 Networks (FFIV) at the expense of Intuitive Surgical (ISRG) and Free McMoran (FCX). What's the current outlook for the CANSLIM 8? PatternDNA projections are derived from a pool of 18 U.S. stocks. Expected returns...
-
Wedbush Expects A Better Q2 For Cutera (CUTR)
Tuesday, May 3, 2011 - 9:17am | 81According to a recent report, Wedbush expects Cutera (NASDAQ: CUTR) to make a big improvement after a terrible quarter. In the report, Wedbush said, "CUTR expects Q2 revenues to show growth on both a sequential and year/year basis. This would mark CUTR's best top-line growth in more than two years...
-
Duncan-Williams Reiterates Buy on Exactech (EXAC)
Tuesday, May 3, 2011 - 8:52am | 80Duncan-Williams is out with its report on Exactech (NASDAQ: EXAC), reiterating Buy. In a note to clients, Duncan-Williams writes, "We are maintaining our 2011 revenue and EPS estimates of $207 million and $1.15, respectively. This represents 9% revenue growth and 34% EPS growth compared to 2010....
-
Boston Scientific Announces CE Mark Approval and First Use of Blazer Open-Irrigated Catheter in Europe
Tuesday, May 3, 2011 - 8:32am | 65Boston Scientific Corporation (NYSE: BSX) today announced CE Mark approval and first use in Europe of its Blazer™ Open-Irrigated Catheter, the Company's latest radiofrequency ablation catheter designed to treat a variety of arrhythmias such as atrial fibrillation, atrial flutter, ventricular...